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Background: Erythropoiesis-stimulating agents (ESAs) reduce the need for red blood cell transfusions; however, they increase the risk of
thromboembolic events and mortality. The impact of ESAs on quality of life (QoL) is controversial and led to different recommendations
of medical societies and authorities in the USA and Europe. We aimed to critically evaluate and quantify the effects of ESAs on QoL in
cancer patients.
Methods: We included data from randomised controlled trials (RCTs) on the effects of ESAs on QoL in cancer patients. Randomised
controlled trials were identified by searching electronic data bases and other sources up to January 2011. To reduce publication and outcome
reporting biases, we included unreported results from clinical study reports. We conducted meta-analyses on fatigue- and anaemia-related
symptoms measured with the Functional Assessment of Cancer Therapy-Fatigue (FACT-F) and FACT-Anaemia (FACT-An) subscales (primary
outcomes) or other validated instruments.
Results: We identified 58 eligible RCTs. Clinical study reports were available for 27% (4 out of 15) of the investigator-initiated trials and
95% (41 out of 43) of the industry-initiated trials. We excluded 21 RTCs as we could not use their QoL data for meta-analyses, either
because of incomplete reporting (17 RCTs) or because of premature closure of the trial (4 RCTs). We included 37 RCTs with 10 581
patients; 21 RCTs were placebo controlled. Chemotherapy was given in 27 of the 37 RCTs. The median baseline haemoglobin (Hb) level
was 10.1 gdl–1; in 8 studies ESAs were stopped at Hb levels below 13 gdl–1 and in 27 above 13 gdl–1. For FACT-F, the mean
difference (MD) was 2.41 (95% confidence interval (95% CI) 1.39–3.43; Po0.0001; 23 studies, n¼ 6108) in all cancer patients and 2.81
(95% CI 1.73–3.90; Po0.0001; 19 RCTs, n¼ 4697) in patients receiving chemotherapy, which was below the threshold (X3) for a
clinically important difference (CID). Erythropoiesis-stimulating agents had a positive effect on anaemia-related symptoms (MD 4.09; 95%
CI 2.37–5.80; P¼ 0.001; 14 studies, n¼ 2765) in all cancer patients and 4.50 (95% CI 2.55–6.45; Po0.0001; 11 RCTs, n¼ 2436) in patients
receiving chemotherapy, which was above the threshold (X4) for a CID. Of note, this effect persisted when we restricted the analysis to
placebo-controlled RCTs in patients receiving chemotherapy. There was some evidence that the MDs for FACT-F were above the
threshold for a CID in RCTs including cancer patients receiving chemotherapy with Hb levels below 12 gdl–1 at baseline and in RCTs
stopping ESAs at Hb levels above 13 gdl–1. However, these findings for FACT-F were not confirmed when we restricted the analysis to
placebo-controlled RCTs in patients receiving chemotherapy.
Conclusions: In cancer patients, particularly those receiving chemotherapy, we found that ESAs provide a small but clinically important
improvement in anaemia-related symptoms (FACT-An). For fatigue-related symptoms (FACT-F), the overall effect did not reach the
threshold for a CID.
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Erythropoiesis-stimulating agents (ESAs) reduce the need for red
blood cell transfusions (Bohlius et al, 2006b; Ludwig et al, 2009;
Tonelli et al, 2009) and may improve quality of life (QoL);
however, they increase the risk of thromboembolic events and
death. A large meta-analysis based on individual patient data (IPD)
from 53 randomised controlled trials (RCTs) demonstrated a
statistically significant, 17% higher risk of mortality during the
active study phase in cancer patients who received ESAs compared
with controls (Bohlius et al, 2009a, b). An increased risk of
mortality was also reported in each of the more recent systematic
reviews and meta-analyses, which were not funded by the
pharmaceutical industry (Bennett et al, 2008; Tonelli et al, 2009;
Tonia et al, 2012; Grant et al, 2013) but in none of the systematic
reviews and meta-analyses sponsored by the pharmaceutical
industry (Aapro et al, 2008b; Glaspy et al, 2010). Several meta-
analyses have shown that ESAs increase the risk of thromboem-
bolic events in cancer patients (Bohlius et al, 2006a, b; Seidenfeld
et al, 2006; Aapro et al, 2008b, 2009; Bennett et al, 2008; Ludwig
et al, 2009; Tonelli et al, 2009); the effects of ESAs on tumour
progression remain uncertain (Aapro et al, 2012).
The impact of ESAs on QoL is controversial. Positive findings
from observational studies (Glaspy et al, 1997; Demetri et al, 1998;
Gabrilove et al, 2001; Quirt et al, 2001; Cella et al, 2003) and
clinical trials (Littlewood et al, 2001; Fallowfield et al, 2002; Chang
et al, 2005; Wilkinson et al, 2006) have not been confirmed in more
recent RCTs (Smith et al, 2008; Hoskin et al, 2009; Engert et al,
2010; Fujisaka et al, 2011; Nitz et al, 2011). Previous meta-analyses
have demonstrated that ESAs effectively reduce fatigue-related
symptoms in cancer patients (Minton et al, 2008, 2010; Tonelli
et al, 2009). However, these meta-analyses were restricted to the
published literature and may be compromised by publication and
outcome reporting biases (Egger and Smith, 1998; Dwan et al,
2011; Redmond et al, 2013). Publication bias refers to the fact that
studies with positive results are more likely to be published
compared with studies with negative results (Egger and Smith,
1998). Outcome reporting bias refers to the selective reporting of
outcomes in a published study, where mainly the most statistically
significant results or the ones meeting the authors’ assumptions are
reported (Dwan et al, 2011; Redmond et al, 2013). Meta-analyses
including only published results may be prone to bias and
overestimate treatment effects.
We aimed to critically evaluate and quantify the effects of ESAs
on QoL in cancer. We systematically reviewed and meta-analysed
RCTs that compared ESAs with controls in cancer patients. Our
objectives were to examine the effects of ESAs on patient-rated
fatigue- and anaemia-related symptoms and to identify groups of
patients who may benefit most from treatment with ESAs. To
reduce potential publication and outcome reporting biases, we
included unpublished and unreported data.
MATERIALS AND METHODS
Study selection and data extraction. We included RCTs that
compared epoetin or darbepoetin with placebo or best standard of
care and assessed fatigue- and anaemia-related symptoms in cancer
patients receiving or not receiving anticancer treatment. We
excluded trials with high-dose myeloablative chemotherapy regi-
mens followed by stem cell transplantation, trials in patients with
myelodysplastic syndromes and acute leukaemia, and trials using
ESAs for short-term pre-operative treatment. We included studies
that prospectively evaluated QoL using a validated or generally
accepted instrument and a planned sample size of 450
participants per study arm or 100 participants in total. Trials
using different types of iron supplementation were included and
evaluated in stratified analyses.
We updated literature searches from our previous meta-analyses
on ESAs (Bohlius et al, 2006a, b, 2009a, b) in Medline, Embase,
Cochrane Central Register of Controlled Trials and databases of
conference proceedings for the years 2008 to January 2011 (for
details, see Supplementary Webappendix Table 1). We screened
the reference lists of relevant meta-analyses and clinical trials
registries (http://clinicaltrials.gov/; http://www.isrctn.org/). Four
reviewers (AM, JB, NR and TT) worked in pairs and independently
determined study eligibility. Data on study characteristics, study
quality and outcomes were extracted by one reviewer (TT) and
checked for accuracy by another (JB). Our primary sources of data
extraction were the published study documents. We complemented
these data with information from study protocols and reports,
which we had obtained from ESA manufacturers (Amgen,
Thousand Oaks, CA, USA; Johnson & Johnson, New Brunswick,
NJ, USA; Hoffmann-La Roche, Basel, Switzerland) and clinical
study groups for a previous IPD meta-analysis (Bohlius et al,
2009a, b). For that meta-analysis, we had identified published and
unpublished trials through electronic searches of published
abstracts and articles, screening of clinical trials registries and
Oncologic Drugs Advisory Committee hearing documents, and
contacting ESA manufacturers and experts in the field. We had
obtained clinical study reports as requested for 98% (48 out of 49)
of the trials initiated by the ESAs manufacturers and 36% (5 out of
14) of the trials run by clinical study groups, for details see Bohlius
et al (2009a, b). In addition, we searched for QoL results in clinical
trials registries (http://clinicaltrials.gov/; http://www.isrctn.org/).
Outcomes. Our primary outcomes were fatigue- and anaemia-
related symptoms measured with the Functional Assessment
of Cancer Therapy-Fatigue (FACT-F) subscale and the FACT-
Anaemia (FACT-An) subscale. The FACT-F includes 13 fatigue-
related questions (range of scale 0–52). The FACT-An (range of
scale 0–80) includes the 13 fatigue-related items plus 7 anaemia-
related questions, for example, dizziness, headaches, pain in chest
and trouble walking. These instruments are widely used in ESA
trials, are highly responsive to change, and have good convergent
and discriminant validity (Cella, 1997, 2007; Yellen et al, 1997;
Cella et al, 2002b). Secondary outcomes included changes in the
cancer-specific FACT-G total score (range 0–108) and the
subscales on physical, functional and social/family well-being
(range 0–28) and emotional well-being (range 0–24). For
sensitivity analyses, we included the fatigue- and anaemia-related
subscales from studies that used instruments other than FACT-F
and FACT-An, that is, EORTC QLQ-C30 (Aaronson et al, 1993),
SF-36 (Ware and Sherbourne, 1992), FACT-An subscale non-
fatigue items (Cella, 1997), FACT-An full scale (Cella, 1997) and
visual analogue scales (VAS) assessing energy, daily activities and
overall health or QoL. For each instrument, we predefined the
specific domain that best corresponded to fatigue- and anaemia-
related symptoms, physical, functional, social/family, emotional
well-being and overall QoL as measured by FACT-F, FACT-An,
FACT-G and its subscales. We defined a clinically important
difference (CID) as a mean difference (MD) of X3 for FACT-F
(Cella et al, 2002b) and X4 for FACT-An (D Cella, personal
communication, March 2010). For standardised effect sizes, an
effect size of 0.20–0.50 s.d. units was considered small but clinically
important, whereas effect sizes of 0.50–0.80 and 40.80 were
considered to be moderate and large differences, respectively
(Sloan and Dueck, 2004; Sloan et al, 2006).
Statistical methods. Results from individual studies were expressed
either as differences in mean changes from baseline to study end or
as effect sizes. Effect sizes were calculated as the differences in mean
values at the end of treatment divided by the pooled s.d. (Cohen’s d)
(Cohen, 1988). If the required data were not reported, we used
approximations (Reichenbach et al, 2007) to calculate differences
or s.d. Data were analysed according to the intention-to-treat
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approach, using the last observation carried forward if data were
missing. In sensitivity analyses, we analysed the data measured closest
to week 12, a time point frequently considered in ESA trials. We used
random-effects meta-analyses to combine trials and quantified
heterogeneity with the I2 statistic (Higgins et al, 2003).
In stratified analyses, we aimed to identify patient character-
istics, treatment strategies and aspects of study design associated
with the effect of ESAs on QoL, see Supplementary Webappendix
Table 2. Tests of interactions and trends were obtained from
univariate random-effects meta-regression models (Thompson and
Sharp, 1999). Analyses were conducted in the entire data set,
including all RCTs, only in chemotherapy trials and only in
placebo-controlled RCTs in patients receiving chemotherapy. We
investigated the association between trial size and treatment effects
in funnel plots and regression tests (Sterne and Egger, 2001). To
adjust for potential publication bias, we used the trim and fill
method (sensitivity analysis) (Duval 2005). Results are presented as
MDs or standardised MDs (SMDs) with 95% confidence intervals
(95% CIs). We estimated treatment response as the proportion of
patients achieving a CID (threshold 3 for FACT-F and 4 for FACT-
An subscales). To estimate this treatment response, we used
hypothetical control group risks and the SMD and the correspond-
ing 95% CI (Furukawa and Leucht, 2011). We derived numbers
needed to treat (NNT) to cause one additional treatment response
on FACT-F or FACT-An in patients receiving ESA compared with
control from the inverse of the absolute difference between
experimental and hypothetical control group risks. Study end
points, eligibility criteria, search methods and main analyses were
defined in a protocol. All analyses were performed using Stata 10.0
(StataCorp, College Station, TX, USA).
RESULTS
Number of eligible, included and excluded studies. We identi-
fied 58 eligible RCTs. Clinical study reports were available for 27%
(4 out of 15) of the trials run by clinical study groups and 95%
(41 out of 43) of the trials initiated by the ESAs manufacturers. Of
the 58 eligible RCTs, we excluded 21 RTCs for the following
reasons: QoL data were not reported because of premature closure
of the trials (Machtay et al, 2007; Thomas et al, 2008; AGO-OVAR
2.7; CR002305); or data reporting was too incomplete to allow any
analysis (Rose et al, 1994; Dammacco et al, 2001; Quirt et al, 2001;
Thomas et al, 2002; INT-1; INT-3; Leyland-Jones et al, 2005; Goss
et al, 2005; Aapro et al, 2008a; Suzuki et al, 2008; EPO-GER-20;
Gupta et al, 2009; Ray-Coquard et al, 2009; Yoshizaki et al, 2010;
Untch et al, 2011; CDR0000069148; Moebus et al, 2013) (Figure 1).
Finally, we included 37 studies with 10 581 patients randomised
(Abels, 1993; Case et al, 1993; Henry and Abels, 1994; Thatcher
et al, 1999; Littlewood et al, 2001; Huddart et al, 2002; Kotasek
et al, 2002, 2003; Osterborg et al, 2002; Vansteenkiste et al, 2002;
Boogaerts et al, 2003; Hedenus et al, 2003; Iconomou et al, 2003;
Milroy et al, 2003; P-174; Chang et al, 2005; Debus et al, 2005;
Mystakidou et al, 2005; O’Shaughnessy et al, 2005; Savonije et al,
2005; Witzig et al, 2005; Wilkinson et al, 2006; Charu et al, 2007;
304 documents assessed for eligibility 
58 RCTs on ESAs vs control in cancer patients assessing QoL
42 documents 
retrieved
239 documents retrieved 23 documents retrieved
21studies excluded: 
Incomplete data (n = 17)
QoL not reported due to 
premature closure (n = 4)
37 RCTs eligible for QoL analysis, n = 10,581 patients randomised
246 studies excluded: 
No RCT (n = 79)
All patients ESAs (n = 38)
No of patients too small (n = 26)
Surgery (n = 10)
Epo versus Darb (n = 6)
Duplicates (n = 11)
Studies ongoing (n = 29)
Not assessing QoL (n = 23)
Other reasons (n = 22)
No validated QoL instruments (n = 1)
Study in children (n = 1)
853 excluded
by abstract 
screening
601 excluded by 
abstract screening
260 excluded by 
screening
499 studies were identified through 
previous reviews, reference lists, 
conference proceedings, clinical 
trials registries, other sources
643 records were identified through 
database searching in 2009 
(Medline, Embase, Central) after 
duplicates were removed
876 records were identified  
through database searching in 2011 
(Medline, Embase, Central) 
after duplicates removed
Figure 1. PRISMA flow diagram showing the identification of eligible trials (Moher et al, 2009).
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Wright et al, 2007; Gordon et al, 2008; Krzakowski, 2008; Pirker
et al, 2008; Smith et al, 2008; Strauss et al, 2008; Christodoulou
et al, 2009; Hernandez et al, 2009; Hoskin et al, 2009; OBE/EPO-
INT-03; Tsuboi et al, 2009; Winquist et al, 2009; Engert et al, 2010;
Pronzato et al, 2010).
Characteristics of included studies. Characteristics of included
studies are shown in Table 1 and Supplementary Webappendix
Tables 3–5. Quality of life was the primary end point in 11 (30%)
studies, a secondary end point in 25 trials, and was not mentioned
as a study end point in one study. Most studies (n¼ 23) used the
FACT-F subscale and/or (n¼ 14) the FACT-An subscale. Among
the studies not reporting FACT-F or FACT-An, three studies
reported the total score of the full FACT-An scale (47 items), one
study used EORTC QLQ-C30, one SF-36 and five studies used
VAS. Twenty-one (57%) studies were placebo controlled, 11 (30%)
reported sample size calculations for a QoL end point, 9 (24%)
defined a QoL hypothesis, 4 (11%) reported definitions for a
clinically important change and 4 (11%) reported percentages of
patients completing QoL questionnaires (submission rates).
Chemotherapy was given in 27 of the 37 studies included (73%).
Radiotherapy or radiochemotherapy was given in two studies and
no anticancer treatment was given in six (16%). In one study,
o70% of the included patients received chemotherapy (P-174) for
another study, the underlying anticancer therapy was unclear
(Winquist et al, 2009). These two studies were categorised as
‘other/unclear’. Short-acting ESAs (epoetin a, b or d) were given in
28 (76%) studies and darbepoetin in 9 studies. About half (20
studies, 54%) of the studies included patients with solid tumours;
five included patients with haematological malignancies. Of the 37
studies included, 14 studies had a mean/median haemoglobin (Hb)
at baseline below 10 g dl–1; the lowest average Hb at baseline was
8.8 g dl–1 (P-174). Seventeen studies included patients with Hb
baseline levels between 10 and 12 g dl–1 and six studies included
patients with Hb baseline levels above 12 g dl–1. The highest
average Hb at baseline was 13.6 g dl–1 (Thatcher et al, 1999; Hoskin
et al, 2009). The median baseline Hb level across all trials was
10.1 g dl–1. Most studies gave ESAs for 9–16 weeks (18 studies,
49%) or until the end of chemotherapy (13 studies, 35%). None of
the included studies recommended stopping treatment at a Hb
level of 12 g dl–1 or below. Eight studies (22%) stopped ESAs at Hb
levelsp13 g dl–1 and 27 (73%) at Hb levels413 g dl–1. Two studies
did not report the Hb target. Iron supplementations were given
according to a patient’s transferrin saturation or ferritin levels
(29 studies) or according to a fixed schedule (7 studies). All but
three studies were funded by the pharmaceutical industry.
Main results for the effects of ESAs on QoL. The analysis of
FACT-F included results from 23 studies; 17 stemming from the
published literature and 6 from clinical study reports. Of the 7624
patients initially randomised, 6108 (80%) were included in the
analysis. Fatigue-related symptoms improved in patients receiving
ESAs compared with controls, with a MD in FACT-F of 2.41 (95%
CI 1.39–3.43, Po0.001; Figure 2), which is below the threshold
(X3) of a CID. The SMD was 0.22 (95% CI 0.13–0.32, Po0.001).
There was moderate heterogeneity among trials (I2¼ 65%) and
some evidence for funnel plot asymmetry (Egger’s test P¼ 0.07;
Figure 3A). The CID for FACT-F (43) was not reached in any of
the analysis subsets, that is, all trials (see above), chemotherapy
trials only (MD 2.81, 95% CI 1.73–3.90, 19 studies, n¼ 4697) and
placebo-controlled chemotherapy trials (MD 1.78, 95% CI
0.82–2.73, 10 studies, n¼ 2714). The analysis of FACT-An included
results from 14 studies; 7 were stemming from the published
literature and 7 from clinical study reports. Of 3519 patients
randomised, 2765 (79%) were included in the analysis. Anaemia-
related symptoms improved with a MD in FACT-An of 4.09 (95%
CI 2.37–5.80, P¼ 0.001; Figure 2), which is above the threshold
(X4) of a CID. The SMD was 0.30 (95% CI 0.17–0.42, P¼ 0.003).
There was moderate heterogeneity among trials (I2¼ 63%) and no
evidence for funnel plot asymmetry (Egger’s test P¼ 0.38;
Figure 3B). Of note, the CID for FACT-An (44) was reached
throughout all analysis subsets, that is, all trials (see above),
chemotherapy trials only (MD 4.50, 95% CI 2.55–6.45, 11 studies,
n¼ 2436) and placebo-controlled chemotherapy trials (MD 4.55,
95% CI 1.29–7.80, 3 studies, n¼ 721). Results for FACT-F and
FACT-An were similar when based on the data observed closest to
week 12 (see Supplementary Webappendix Table 6). When using
trim and fill methods, the overall result for FACT-F was reduced
from MD 2.41 (95% CI 1.39 to 3.43) to MD 0.96 (95% CI  0.23 to
2.14); while the overall result for FACT-An remained unchanged
(MD 4.09; 95% CI 2.37–5.80). There was little evidence for
clinically important improvements in overall QoL, physical,
functional, social or emotional well-being measured with FACT-
G and its subscales, with MDs ranging from 0.25 (95% CI  0.09
to 0.59) for emotional well-being to 1.45 (95% CI 0.02 to 2.88)
for FACT-G overall (Supplementary Webappendix Figure 1).
Sensitivity analyses that included studies using other instruments
produced similar results for fatigue- or anaemia-related
symptoms, overall QoL and subscales (Supplementary Webappendix
Table 6).
Stratified analyses for FACT-F and FACT-An. We conducted
stratified analyses to identify groups of patients and treatment
strategies in which ESAs had more effect on fatigue- and anaemia-
related symptoms. Concerning fatigue-related symptoms, patients
receiving chemotherapy showed more pronounced effects than
patients receiving radiotherapy or no therapy (test for interaction
P¼ 0.079); however, in patients receiving chemotherapy the
threshold for a CID was not met, see Table 2. Within the group
of chemotherapy studies, trials including patients with Hb baseline
below 12 g dl–1 achieved differences above the CID threshold in
contrast to studies with Hb baseline above 12 g dl–1, however, the
difference between these groups of trials was not statistically
significant (P for interaction 0.11). Chemotherapy trials stopping
ESAs at Hb levels 413 g dl–1 achieved differences above the CID
threshold in contrast to studies stopping ESAs at Hb levels
p13 g dl–1; however, differences between these groups of studies
were of borderline statistical significance (P for interaction 0.053).
When we restricted the analysis to placebo-controlled chemo-
therapy trials, the MDs for FACT-F in trials including patients with
Hb o12 g dl–1 at baseline and trials stopping ESAs at Hb levels
413 g dl–1 were below the CID threshold. The beneficial effect of
ESAs on fatigue increased with the number of injections per week
(test for trend P¼ 0.032 in all trials and P¼ 0.044 in chemotherapy
trials). When we further restricted this analysis to placebo-
controlled trials, the test for trend was not statistically significant
(test for trend P¼ 0.134). We observed that open-label studies
showed MDs for FACT-F, which were above the CID and larger
than the results stemming from placebo-controlled trials (test for
interaction P¼ 0.054 in all trials and P¼ 0.083 in chemotherapy
trials). There was some evidence that trials with QoL as primary
end point achieved better results than trials with QoL as secondary
end point (test for interaction P¼ 0.027 in all trials and P¼ 0.091
in chemotherapy trials), however, this was not confirmed when we
further restricted the analysis to placebo-controlled trials. Of note,
the CID was not met in trials in which a majority of patients had
advanced disease (470% of patients with metastatic/advanced
disease). Results stemming from full publications and clinical study
reports were similar. Studies with and without industry funding
reported similar effect estimates. The corresponding results for
anaemia-related symptoms (FACT-An) were similar to the FACT-
F results, but were based on fewer trials; and tests for interaction
failed to reach conventional levels of statistical significance, see
Table 3. Additional stratified analyses for FACT-F and FACT-An
are shown in Supplementary Webappendix Tables 7 and 8.
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Percentage of patients achieving a CID and NNT. We estimated
the percentage of patients achieving a CID and corresponding
NNTs based on hypothetical control groups. With a hypothetical
response rate of 20% in the control group, the response rate in
patients receiving ESAs is 27% (95% CI 24%–30%) for FACT-F
and 29% (95% CI 25%–34%) for FACT-An with corresponding
NNTs of 14 (95% CI 10–26) and 10 (95% CI 7–19). With a
hypothetical response rate of 40% in the control group, the
response rate in patients receiving ESAs is 49% (95% CI 45–52) for
FACT-F and 52% (95% CI 47%–57%) for FACT-An with
corresponding NNTs of 11 (95% CI 8–19) and 8 (95% CI 5–14).
DISCUSSION
We found that ESAs provide a small but clinically important
improvement in anaemia-related symptoms (FACT-An), which
was confirmed when the analysis was restricted to placebo-
controlled RCTs in patients receiving chemotherapy. For fatigue-
related symptoms (FACT-F), the overall effect did not reach the
threshold for a CID. For FACT-F, there was some evidence that
treatment effects were above the threshold for a CID in RCTs in
patients receiving chemotherapy with Hb levels below 12 g dl–1 at
baseline and in RCTs stopping ESAs at Hb levels above 13 g dl–1.
However, these findings for FACT-F were not confirmed when we
restricted the analysis to placebo-controlled RCTs in patients
receiving chemotherapy.
To reduce publication and outcome reporting biases, we
included unpublished and unreported results from clinical study
reports. This allowed us to include more studies and patients than
previous meta-analyses (Tonelli et al, 2009; Minton et al, 2010;
Tonia et al, 2012; Grant et al, 2013), and to explore the effects of
ESAs in different populations. Clinical study reports are not peer
reviewed and the quality of these reports and the validity of the
reported study data is uncertain. However, when we restricted our
analyses to data from full publications our overall conclusions did
not change. Similarly, our conclusions did not change when we
conducted trim and fill analyses to adjust for potential publication
bias. Our study does not confirm a CID for FACT-F, which had
been reported in two previous literature-based meta-analyses
(Minton et al, 2008, 2010; Tonelli et al, 2009). Our findings for
FACT-An are more conservative compared with a recent meta-
analysis based on the published literature (Tonia et al, 2012). To
account for the current licensed indication and to reduce the
Table 1. Characteristics of included randomised controlled trials
Characteristic N of studies (%)
Total number of studies 37 (100)
Number of patients randomised (median (range)) 259 (45–1379)
Year of publication (median (range)) 2005 (1993–2010)
Baseline Hb
p10gdl–1 14 (37.84)
10–12gdl–1 17 (45.95)
412gdl–1 6 (16.22)
Tumour type
Solid 20 (54.05)
Haematological 5 (13.51)
Solid and haematological 12 (32.43)
Drug
Epoetin a 23 (62.16)
Epoetin b 4 (10.81)
Epoetin d 1 (2.70)
Darbepoetin 9 (24.32)
Anticancer treatment
Chemotherapy 27 (72.97)
Radiotherapy 2 (5.41)
No anticancer therapy 6 (16.22)
Other/unclear 2 (5.41)
Duration of ESA treatment
o9 Weeks 2 (5.41)
9–16 Weeks 18 (48.65)
X17 Weeks 4 (10.81)
Until end of chemotherapy 13 (35.14)
Planned weekly ESA dose
o40 000 U epo a/d or 30,000 U epo b or 100 mg darbepo 9 (24.32)
¼ 40000 U epo a/d or 30,000 U epo b or 100mg darbepo 9 (24.32)
440000 U epo a/d or 30,000 U epo b or 100mg darbepo 13 (35.14)
Other (e.g., weight based or Hb based) 6 (16.22)
Frequency of ESA administration
TIW 19 (51.35)
QW 11 (29.73)
p Q2W 6 (16.22)
Other 1 (2.70)
Target Hb
p13gdl–1 8 (21.62)
413–15gdl–1 27 (72.97)
Not reported 2 (5.41)
Placebo controlled
Yes 21 (56.76)
No 16 (43.24)
Study completed?
Terminated/halted 7 (18.92)
Completed 30 (81.08)
Year last patient randomised
o1995 5 (13.51)
1995–1999 4 (10.81)
2000–2004 18 (48.65)
2005–2009 7 (18.92)
Not reported 3 (8.11)
Table 1. ( Continued )
Characteristic N of studies (%)
Disease stage
470% Advanced disease 16 (43.24)
470% Early disease 3 (8.11)
Other 7 (18.92)
Not reported 11 (29.73)
QoL primary end point
Yes 11 (29.73)
No 26 (70.27)
Study industry funded
Yes 34 (91.89)
No 3 (8.11)
Abbreviations: ESA¼ erythropoiesis-stimulating agents; Hb¼ haemoglobin; QoL¼quality
of life; QW¼once per week; pQ2W¼ every second week or less frequent; TIW¼ three
times per week.
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influence of placebo effects (a potential bias in self-reported
measures such as fatigue- and anaemia-related symptoms), we
conducted additional analyses restricted to (1) chemotherapy RCTs
regardless of blinding and (2) only placebo-controlled chemother-
apy RCTs. However, there were only few placebo-controlled RCTs
reporting QoL outcomes for patients receiving chemotherapy,
which limited our ability to conduct stratified analyses in this
setting. For example, both in the overall analyses and in those
restricted to chemotherapy studies, FACT-F results were more
favourable in studies that chose QoL as primary end point,
compared with those that chose QoL as secondary end point. Only
one study evaluating FACT-F as primary end point in patients
receiving chemotherapy was placebo controlled, and so we cannot
gauge the extent to which the effect observed for primary vs
secondary end point was confounded by lack of blinding. The
design of the included studies did not permit us to estimate the
relative benefit of ESAs in Hb responders vs non-responders. This
would have required RCTs that identified responders in a run in
period and then randomised these responders to either stop or
continue ESAs. Finally, decreased QoL in cancer patients is affected
by factors other than anaemia. Correction of a single factor, as did
the studies included in our meta-analyses, may not have adequately
reflected the complex pathophysiological and psychological
dimensions of patient-reported QoL.
Several limitations of our study underscore the need for open
access to all clinical trials results including study protocols,
amendments, reports and IPD as currently discussed at the
European Medicines Agency (Eichler et al, 2012). First, the quality
Random effects
weight (%) Study (author, year)
Mean difference in changes
(95% confidence intervals) 
FACT-An (scale: 0–80)
Winquist, 2009 –0.60 (–9.64, 8.44) 2.85
Wright, 2007 3.90 (–4.56, 12.36) 3.15
OBE-EPO-INT-03
Huddart, 2002
O'Shaughnessy, 2005 6.40 (0.81, 11.99) 5.55
Christodoulou, 2009 3.50 (–1.15, 8.15) 6.78
Savonije, 2005 5.84 (1.35, 10.33) 7.03
Hoskin, 2009
Pronzato, 2010
Littlewood, 2001 6.60 (2.83, 10.37) 8.18
Milroy, 2003 9.30
Chang, 2005 6.59 (3.79, 9.39) 9.94
Debus, 2005
Osterborg, 2002
Subtotal  (I-squared = 62.7%, P = 0.001) 4.09 (2.37, 5.80) 100.00
FACT-F (scale: 0–52)
OBE-EPO-INT-03
Iconomou, 2003 5.60 (0.91, 10.29) 2.84
Kotasek, 2002
Kotasek, 2003 1.10 (–2.76, 4.96) 3.51
Charu, 2007 3.80 (–0.04, 7.64) 3.54
Gordon, 2008 –0.20 (–3.82, 3.42) 3.75
Savonije, 2005 5.15 (1.57, 8.73) 3.79
Littlewood, 2001 5.20 (1.69, 8.71) 3.86
Tsuboi, 2009 3.10 (–0.27, 6.47) 3.99
Christodoulou, 2009 3.16 (–0.19, 6.51) 4.02
Boogaerts, 2003 5.00 (1.98, 8.02) 4.37
Osterborg, 2002 2.20 (–0.74, 5.14) 4.47
Hoskin, 2009 0.00 (–2.82, 2.82) 4.60
Witzig, 2005 1.25 (–1.42, 3.92) 4.77
Vansteenkiste, 2002 1.40 (–1.14, 3.94) 4.93
Milroy, 2003
Hernandez, 2009
Pronzato, 2010
Pirker, 2008 0.80 (–1.56, 3.16) 5.15
Chang, 2005 5.40 (3.09, 7.71) 5.20
Hedenus, 2003 2.06 (–0.07, 4.19) 5.42
Debus, 2005
Smith, 2008 –0.54 (–2.18, 1.10) 6.00
Subtotal  (I-squared = 65.3%, P = 0.000) 2.41 (1.39, 3.43) 100.00
Favours control Favours ESA
–10 –5 0 5 10
Figure 2. Forest plots of the effect of ESAs on QoL end points assessed by scales and subscales of the FACT questionnaire. Each solid square
represents the SMD between groups for individual trials, and the size of the square represents the weight of the individual study in the meta-
analysis. Horizontal lines indicate 95% CIs. The dashed vertical lines indicate the thresholds for clinical important differences for FACT-F (X3) and
FACT-An (X4). The width of the diamond shows the 95% CI for the pooled SMD. Trials are sorted by weight. Confidential data are masked.
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of reporting QoL data was low. Both in the published articles and
the clinical study reports key information such as percentage of
patients completing QoL questionnaires was missing or not clearly
reported for the majority of studies. Critical review of clinical study
documents by the academic community may help to improve the
quality of reporting in these reports, which will only be possible
with open access to these documents. Second, we identified
another 16 trials (Kotasek et al, 2002, 2003; Thomas et al, 2002;
Vansteenkiste et al, 2002; Boogaerts et al, 2003; Hedenus et al,
2003; Goss et al, 2005; Mystakidou et al, 2005; Witzig et al, 2005;
Wilkinson et al, 2006; Aapro et al, 2008a; Gordon et al, 2008;
Krzakowski, 2008; Pirker et al, 2008; Strauss et al, 2008; EPO-
GER-20, 2009a) measuring FACT-An that did not or only
incompletely report their FACT-An results and could therefore
not be included in our analyses. Access to IPD may have permitted
to include these studies in our analysis and it is possible that
including these studies would change the results of our analyses.
We unsuccessfully tried to retrieve the IPD and hence evaluated
unpublished aggregated QoL data found in clinical study reports.
However, for results, which were not reported in these
documents, we made no additional attempts to obtain these
results from the investigators. We also assessed whether QoL
results had been published in clinical trials registries, which was
not the case. Finally, our analyses are based on aggregated data
and therefore analyses of variables at patient level, such as Hb at
baseline and stage of disease, are prone to ecological bias
(Berlin et al, 2002). This limitation could be overcome with a
meta-analysis based on IPD, but this was not available for the
current analyses.
When judging the efficacy of ESAs on fatigue- and anaemia-
related symptoms, it is important to differentiate clinical from
statistical significance. The concept of CIDs has been developed to
address this problem (Cella et al, 2002a). However, defining CIDs
is not straightforward. Depending on the clinical context and the
methods selected, the threshold for CID could be set at different
levels. For our primary analyses, we used the definition of Cella
et al (2002b), which was developed to combine anchor- and
distribution-based methods in populations similar to those we
studied. Notably, the CIDs defined for FACT-F and FACT-An
refer to changes from baseline to end of treatment. In our
analyses, we used this yardstick to measure the differences in
mean changes between groups from baseline to treatment,
according to current practice in QoL studies (Tonelli et al, 2009;
Minton et al, 2010).
Harmful effects of ESAs should be balanced against potential
benefits. Previous meta-analyses have consistently shown that
ESAs increase the risk of thromboembolic events in cancer patients
by approximately factor 1.6 (Bohlius et al, 2006a, b; Seidenfeld et al,
2006; Aapro et al, 2008b, 2009; Bennett et al, 2008; Ludwig et al,
2009; Tonelli et al, 2009). Literature-based and IPD meta-analyses
showed increased mortality (Bohlius et al, 2009a, b) or shortened
overall survival in patients receiving ESAs (Bennett et al, 2008;
Tonelli et al, 2009). Whether ESAs are safe for patients undergoing
chemotherapy is a matter of debate. Our meta-analyses, and those
of others based on IPD, have shown that ESAs increased short-
term mortality in patients receiving chemotherapy by approxi-
mately 10% (Bohlius et al, 2009a, b; Ludwig et al, 2009), not
reaching conventional levels of statistical significance. Statistically,
the estimated mortality increase in chemotherapy trials can be
explained by the same underlying effect as that in non-
chemotherapy trials (Bohlius et al, 2009a, b). Clinically, the
increase in mortality associated with ESAs may be less pronounced,
or even absent, in patients receiving chemotherapy than in those
undergoing other anticancer treatments. Two recent studies in
cancer patients receiving chemotherapy did not find evidence for
survival differences in patients receiving ESAs compared with
controls (Engert et al, 2010; Moebus et al, 2013). In these studies,
cancer patients were receiving chemotherapy with a curative intent
and ESAs were stopped at Hb levels of 12 g dl–1 (Engert et al, 2010)
and 14 g dl–1 (Moebus et al, 2013). Nevertheless, current evidence
does not allow to conclude that ESAs are safe in patients receiving
chemotherapy. Basic science studies have evaluated the presence of
erythropoietin (EPO) receptors and its functionality in tumour
cells (Arcasoy et al, 2005; Szenajch et al, 2010; Kumar et al, 2012).
Interestingly, researchers without funding from ESA manufac-
turers were more likely to identify EPO receptors on cancer cells,
EPO-induced signalling events or EPO-induced harmful changes
of cellular function; or to conclude that ESAs had potentially
harmful effects on cancer cells as compared with investigators
receiving funding or being employed by ESA manufacturers
(Bennett et al, 2010). Similarly, of the seven meta-analyses on the
effects of ESAs in cancer patients conducted since 2008 none of the
meta-analyses with funding from ESA manufacturers identified an
increased mortality risk (Aapro et al, 2008b; Glaspy et al, 2010).
In contrast, each of the meta-analyses conducted by researchers
not receiving funding from ESA manufacturers found an
increased risk either for on study mortality or overall survival
0.0
1.0
2.0
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Figure 3. Funnel plots for FACT-F (A) and FACT-An (B). Closed
circles¼ results from published literature, open circles¼ results from
clinical study reports.
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(Bennett et al, 2008; Bohlius et al, 2009a, b; Tonelli et al, 2009;
Tonia et al, 2012; Grant et al, 2013). This observation highlights
the importance of conflicts of interest both in the clinical and the
basic sciences. In the case of ESAs and mortality in cancer patients,
this led to misleading results and conclusions in meta-analyses
funded by the pharmaceutical industry. Of note, in our analyses we
found no evidence that results from industry-funded studies
differed from those not funded by the industry. However, this may
be due to a lack of power in a setting were 490% of studies were
funded by the industry.
Table 2. Stratified analyses for FACT-F in (i) all included RCTs, (ii) RCTs in patients receiving chemotherapy and (iii) placebo-controlled RCTs in patients
receiving chemotherapy
All RCTs Chemotherapy RCTs Placebo-controlled chemotherapy RCTs
FACT-F
Studies/
ESA/
control MD (95% CI) P-valuea
Studies/
ESA/
control MD (95% CI) P-valuea
Studies/
ESA/
control MD (95% CI) P-valuea
Overall 23/3389/2719 2.41 (1.39 to 3.43) 19/2566/2131 2.81 (1.73 to 3.90) 10/1543/1171 1.78 (0.82 to 2.73)
Anticancer treatment 0.218 NA NA
Chemotherapy 19/2566/2131 2.81 (1.73 to 3.90) 19/2566/2131 2.81 (1.73 to 3.90) 10/1543/1171 1.78 (0.82 to 2.73)
Radiotherapy 1/127/134 0.00 ( 2.82 to 2.82) — — — —
None 3/696/454 0.62 ( 1.83 to 3.07) — — — —
Anticancer treatment (condensed) 0.079 NA NA
Chemotherapy 19/2566/2131 2.81 (1.73 to 3.90) 19/2566/2131 2.81 (1.73 to 3.90) 10/1543/1171 1.78 (0.82 to 2.73)
Radiotherapy, none 4/823/588 0.28 ( 1.34 to 1.90) — — — —
Baseline Hb 0.424 0.362 0.153
412gdl–1 3/474/478 0.43 ( 0.94 to 1.80) 2/347/344 0.56 ( 1.01 to 2.13) — —
10–12gdl–1 12/1535/1172 3.07 (1.47 to 4.67) 10/1182/1080 3.31 (1.52 to 5.09) 4/596/573 0.97 ( 0.34 to 2.28)
p10gdl–1 8/1380/1069 2.32 (0.74 to 3.90) 7/1037/707 2.82 (1.57 to 4.08) 6/947/598 2.41 (1.19 to 3.62)
Baseline Hb (condensed) 0.098 0.11 NA
412gdl–1 3/474/478 0.43 ( 0.94 to 1.80) 2/347/344 0.56 ( 1.01 to 2.13)
p12gdl–1 20/2915/2241 2.78 (1.64 to 3.92) 17/2219/1787 3.15 (2.00 to 4.29) 10/1543/1171 1.78 (0.82 to 2.73)
Disease stage 0.025b 0.005b 0.225b
470% not metastatic/advanced 1/168/170 5.40 (3.09 to 7.71) 1/168/170 5.40 (3.09 to 7.71) — —
470% metastatic/advanced 11/1977/1650 1.15 (0.21 to 2.08) 10/1634/1288 1.41 (0.49 to 2.32) 7/1131/879 1.40 (0.37 to 2.42)
Other 6/699/476 3.12 (0.31 to 5.93) 3/219/250 5.59 (2.93 to 8.25) — —
Unknownc 5/545/423 3.21 (1.64 to 4.77) 5/545/423 3.21 (1.64 to 4.77) 3/412/292 2.95 (0.68 to 5.23)
Frequency 0.032b 0.044b 0.134b
pQ2W 6/1170/685 0.85 ( 0.79 to 2.49) 3/474/231 1.37 ( 1.49 to 4.23) 3/474/231 1.37 ( 1.49 to 4.23)
QW 7/849/848 2.20 (0.81 to 3.59) 7/849/848 2.20 (0.81 to 3.59) 4/491/481 1.85 (0.56 to 3.14)
TIW 9/1125/947 3.72 (1.91 to 5.54) 8/998/813 4.22 (2.47 to 5.97) 2/333/220 3.54 (0.62 to 6.46)
Otherc 1/245/239 0.80 ( 1.56 to 3.16) 1/245/239 0.80 ( 1.56 to 3.16) 1/245/239 0.80 ( 1.56 to 3.16)
Target Hb 0.008 0.053 0.105
413–15gdl–1 17/2486/1903 3.00 (1.91 to 4.09) 15/2156/1727 3.17 (2.02 to 4.31) 9/1380/1019 2.06 (1.11 to 3.01)
p13gdl–1 5/846/761  0.13 ( 1.20 to 0.93) 3 /353/349 0.22 ( 1.29 to 1.74) 1/163/152  0.45 ( 2.97 to 2.07)
Not reportedc 1/57/55 5.60 (0.91 to 10.29) 1/57/55 5.60 (0.91 to 10.29) — —
Placebo control 0.054 0.083 NA
Yes 12/2036/1583 1.36 (0.39 to 2.34) 10/1543/1171 1.78 (0.82 to 2.73) 10/1543/1171 1.78 (0.82 to 2.73)
No 11/1353/1136 3.46 (1.77 to 5.16) 9/1023/960 3.85 (1.96 to 5.74) — —
QoL primary end point 0.027 0.091 0.724
Yes 8/850/878 3.87 (1.98 to 5.76) 8/850/878 3.87 (1.98 to 5.76) 1/151/148 1.25 ( 1.42 to 3.92)
No 15/2539/1841 1.53 (0.58 to 2.48) 11/1716/1253 1.93 (0.88 to 2.98) 9/1392/1023 1.87 (0.80 to 2.95)
Source of data 0.907 0.537 0.446
Full publication 17/2628/2053 2.41 (1.35 to 3.47) 13/1805/1465 2.98 (1.97 to 4.00) 8/1258/990 1.92 (0.94 to 2.90)
Clinical study report 6/761/666 2.36 ( 0.37 to 5.10) 6/761/666 2.36 ( 0.37 to 5.10) 2/285/181 1.78 ( 3.14 to 6.69)
Study industry funded 0.362 0.476 NA
Yes 21/3256/2588 2.29 (1.22 to 3.35) 17/2433/2000 2.70 (1.54 to 3.85) 10/1543/1171 1.78 (0.82 to 2.73)
No 2/133/131 3.99 (1.26 to 6.71) 2/133/131 3.99 (1.26 to 6.71) — —
Abbreviations: CI¼ confidence interval; ESA¼ erythropoiesis-stimulating agents; FACT-F¼Functional Assessment of Cancer Therapy-Fatigue subscale; Hb¼ haemoglobin; MD¼mean
difference; NA¼ not applicable; QoL¼quality of life; RCT¼ randomised controlled trial. Frequency:pQ2W¼ every second week or less frequent, QW¼once per week, TIW¼ three times per
week, other¼ frequency changing during the study. Planned weekly ESA dose: high¼440 000U epoetin a/d or 30 000U epoetin b or 100 mg darbepoetin, middle¼ 40 000U epoetin a/d or
30 000U epoetin b or 100mg darbepoetin, low¼o40 000U epoetin a/d or 30 000U epoetin b or 100mg darbepoetin, other¼weight based or Hb based.
aP-value: refers to test for interaction unless otherwise specified.
bTest for trend.
cNot used for interaction/trend test.
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These observations on the harmful effects of ESAs in cancer
patients led to different recommendations of medical societies and
authorities in the USA and Europe (Information for Health
Professions, 2007; Aapro and Link, 2008; Rizzo et al, 2010;
Schrijvers et al, 2010). The FDA and the American Societies of
Clinical Oncology (ASCO) and Hematology (ASH) recommend
the use of ESAs only in anaemic cancer patients receiving
chemotherapy (Rizzo et al, 2010) with palliative treatment intent
(Information for Health Professions, 2007) up to Hb level 12 g dl–1
(Information for Health Professions, 2007) with the goal of
Table 3. Stratified analyses for FACT-An in (i) all included RCTs, (ii) RCTs in patients receiving chemotherapy and (iii) placebo-controlled RCTs in patients
receiving chemotherapy
All RCTs Chemotherapy RCTs
Placebo-controlled chemotherapy RCTs
FACT-An
Studies/
ESA/
control MD (95% CI) P-valuea
Studies/
ESA/
control MD (95% CI) P-valuea
Studies/
ESA/
control MD (95% CI) P-valuea
Overall 14/1466/1299 4.09 (2.37 to 5.80) 11/1310/1126 4.50 (2.55 to 6.45) 3/413/308 4.55 (1.29 to 7.80)
Anticancer treatment 0.709 NA NA
Chemotherapy 11/1310/1126 4.50 (2.55 to 6.45) 11/1310/1126 4.50 (2.55 to 6.45) 3/413/308 4.55 (1.29 to 7.80)
Radiotherapy 1/126/133 1.60 ( 2.24 to 5.44) — — — —
None 1/14/20 3.90 ( 4.56 to 12.36) — — — —
Unclearb 1/16/20 0.60 ( 9.64 to 8.44) — — — —
Anticancer treatment (condensed) 0.458 NA NA
Chemotherapy 11/1310/1126 4.50 (2.55 to 6.45) 11/1310/1126 4.50 (2.55 to 6.45) 3/413/308 4.55 (1.29 to 7.80)
Radiotherapy, none 2/140/153 1.99 ( 1.50 to 5.49) — — — —
Unclearb 1/16/20 0.60 ( 9.64 to 8.44) — — — —
Baseline Hb 0.389 0.567 0.695
412gdl–1 4/511/514 1.64 ( 0.09 to 3.36) 3/385/381 1.91 ( 0.58 to 4.39) 1/40/42 6.40 (0.81 to 11.99)
10–12gdl–1 7/540/477 5.89 (3.31 to 8.48) 5/510/437 6.57 (3.83 to 9.31) — —
o10gdl–1 3/415/308 3.76 (0.87 to 6.64) 3/415/308 3.76 (0.87 to 6.64) 2/373/266 4.14 (0.08 to 8.19)
Baseline Hb (condensed) 0.087 0.137 0.695
412gdl–1 4/511/514 1.64 ( 0.09 to 3.36) 3/385/381 1.91 ( 0.58 to 4.39) 1/40/42 6.40 (0.81 to 11.99)
p12gdl–1 10/955/785 5.09 (2.89 to 7.29) 8/925/745 5.44 (3.04 to 7.83) 2/373/266 4.14 (0.08 to 8.19)
Disease stage 0.06c 0.064c 0.277c
470% not metastatic/advanced 2/208/212 6.55 (4.05 to 9.06) 2/208/212 6.55 (4.05 to 9.06) 1/40/42 6.40 (0.81 to 11.99)
470% metastatic/advanced 7/741/661 2.14 (1.01 to 3.28) 5/711/621 2.15 (0.98 to 3.32) 1/173/176 2.40 (0.84 to 3.96)
Other 3/254/273 5.50 ( 1.43 to 12.43) 2/128/140 7.85 (0.03 to 15.67) — —
Unknownb 2/263/153 5.36 (2.39 to 8.34) 2/263/153 5.36 (2.39 to 8.34) 1/200/90 6.60 (2.83 to 10.37)
Frequency 0.992c 0.801c 0.64c
QW 5/409/424 4.11 (0.96 to 7.25) 4/395/404 4.16 (0.55 to 7.76) 1/40/42 6.40 (0.81 to 11.99)
TIW 9/1057/875 4.09 (1.84 to 6.34) 7/915/722 4.73 (2.10 to 7.36) 2/373/266 4.14 (0.08 to 8.19)
Target Hb 0.25 0.201 NA
413–15gdl–1 12/1279/1107 4.52 (2.63 to 6.41) 9/1123/934 5.10 (2.92 to 7.29) 3/413/308 4.55 (1.29 to 7.80)
p13gdl–1 2/187/192 1.13 ( 1.22 to 3.47) 2/187/192 1.13 ( 1.22 to 3.47) — —
Placebo control 0.985 0.912 NA
Yes 5/443/348 3.91 (1.49 to 6.32) 3/413/308 4.55 (1.29 to 7.80) 3/413/308 4.55 (1.29 to 7.80)
No 9/1023/951 4.12 (1.67 to 6.56) 8/897/818 4.46 (1.74 to 7.17) — —
QoL primary end point 0.471 0.489 NA
Yes 7/568/591 4.69 (1.48 to 7.91) 5/538/551 5.29 (1.58 to 9.00) — —
No 7/898/708 3.21 (1.53 to 4.90) 6/772/575 3.55 (1.60 to 5.50) 3/413/308 4.55 (1.29 to 7.80)
Source of data 0.229 0.24 0.259
Full publication 7/652/469 5.71 (4.02 to 7.39) 5/622/429 6.02 (4.27 to 7.77) 2/240/132 6.54 (3.41 to 9.66)
Clinical study report 7/814/830 3.18 (0.72 to 5.64) 6/688/697 3.48 (0.63 to 6.33) 1/173/176 2.40 (0.84 to 3.96)
Study industry funded 0.864 0.777 NA
Yes 13/1403/1236 4.13 (2.30 to 5.97) 10/1247/1063 4.61 (2.50 to 6.72) 3/413/308 4.55 (1.29 to 7.80)
No 1/63/63 3.50 ( 1.15 to 8.15) 1/63/63 3.50 ( 1.15 to 8.15) — —
Abbreviations: CI¼ confidence interval; ESA¼erythropoiesis-stimulating agents; FACT-An¼ Functional Assessment of Cancer Therapy-Anaemia subscale; Hb¼ haemoglobin; MD¼mean
difference; NA¼ not applicable; QoL¼quality of life; RCT¼ randomised controlled trial. Frequency:pQ2W¼ every second week or less frequent, QW¼once per week, TIW¼ three times per
week, other¼ frequency changing during the study. Planned weekly ESA dose: high X40 000U epoetin a/d or 30 000U epoetin b or 100mg darbepoetin, middle¼ 40 000U epoetin a/d or
30 000U epoetin b or 100mg darbepoetin, low¼o40 000U epoetin a/d or 30 000U epoetin b or 100mg darbepoetin, other¼weight based or Hb based.
aP-value: refers to test for interaction unless otherwise specified.
bNot used for interaction/trend test.
cTest for trend.
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avoiding red blood cell transfusions (Information for Health
Professions, 2007; Rizzo et al, 2010). The FDA and ASCO/ASH
explicitly do not recommend the use of ESAs to improve QoL
because they consider the evidence inconclusive (Information for
Health Professions, 2007; Rizzo et al, 2010). Similarly, in 2007, the
FDA removed the claim for ESA-related QoL improvements in
patients with chronic kidney disease from the product labels
because of a lack of evidence from well-conducted trials. In
contrast, the European Organization for Research and Treatment
of Cancer (Aapro and Link, 2008) and the European Society of
Medical Oncology (Schrijvers et al, 2010) recommend the use of
ESAs to improve QoL in cancer patients.
Our overall analyses showed a small yet clinically important
improvement for FACT-An, which was confirmed when the
analysis was restricted to placebo-controlled RCTs in patients
receiving chemotherapy. Of 100 patients treated, approximately 10
to 13 patients will have a clinically important improvement of
anaemia-related symptoms, which can be attributed to ESA
treatment. However, in patients treated with a curative approach
it is unlikely that the observed benefits will outweigh the negative
effects of ESAs on short-term mortality and thromboembolic
events. Studies in cancer patients receiving chemotherapy with a
palliative intent and receiving ESAs in accordance to current
guideline recommendations (i.e., starting ESAs at Hb o10 g dl–1
and stopping at 12 g dl–1) and reporting QoL outcomes were not
available. In this setting, the impact of ESAs on QoL remains
unclear.
CONCLUSION
We found that ESAs provide a small but clinically important
improvement in anaemia-related symptoms (FACT-An). For
fatigue-related symptoms (FACT-F), the overall effect did not
reach the threshold for a CID.
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